Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $37
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
Wells Fargo Initiates Coverage On Denali Therapeutics with Overweight Rating, Announces Price Target of $35
Guggenheim reaffirms top pick in Biotech after Q3 results
Should Earnings Beat Require Action From Denali Therapeutics Stock Investors?
Is Denali Therapeutics (DNLI) Already Priced Right For Its Cash Flow?
Denali Therapeutics (DNLI) Earnings Beat Puts Valuation Back In Focus
Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars Nearly ...
Denali (DNLI) Q3 2026 Earnings Call Transcript
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42
Denali Therapeutics Inc. Q3 2026 Earnings Call Summary
Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24
BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target
Denali Therapeutics Q3 Earnings Call Highlights
Denali Therapeutics soars on earnings beat
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
UPDATE: Denali Therapeutics Q3 Adj. EPS $(0.64) Misses $(0.53) Estimate, Sales $17.778M Beat $10.657M Estimate
Denali Therapeutics Q3 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.